QUILLIVANT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Quillivant, and what generic alternatives are available?
Quillivant is a drug marketed by Nextwave and is included in one NDA. There are seven patents protecting this drug.
The generic ingredient in QUILLIVANT is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Quillivant
A generic version of QUILLIVANT was approved as methylphenidate hydrochloride by SPECGX LLC on November 27th, 1998.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for QUILLIVANT?
- What are the global sales for QUILLIVANT?
- What is Average Wholesale Price for QUILLIVANT?
Summary for QUILLIVANT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for QUILLIVANT |
| Drug Sales Revenues: | Drug sales revenues for QUILLIVANT |
| What excipients (inactive ingredients) are in QUILLIVANT? | QUILLIVANT excipients list |
| DailyMed Link: | QUILLIVANT at DailyMed |
US Patents and Regulatory Information for QUILLIVANT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nextwave | QUILLIVANT XR | methylphenidate hydrochloride | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 202100-001 | Sep 27, 2012 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Nextwave | QUILLIVANT XR | methylphenidate hydrochloride | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 202100-001 | Sep 27, 2012 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Nextwave | QUILLIVANT XR | methylphenidate hydrochloride | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 202100-001 | Sep 27, 2012 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
